Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of concomitant vaccination with IC51 and Havrix 1440 in healthy subjects
2005-003526-25Phase 3Completed
- Sponsor
- Intercell AG
- Start
- Sep 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Japanese encephalitis (JE) and hepatitis A (HAV) comparing IC51 + Havrix 1440, IC51 + placebo and Havrix 1440 + placebo (3 arms). Primary endpoints: Geometric mean titer of anti-JEV neutralizing antibodies at day 56 and Geometric mean titer of anti-hepatitis A virus antibodies at day 28. Started Sep 2005; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccineHepatitis A virus vaccine
03
Conditions
Japanese encephalitis (JE)hepatitis A (HAV)
Beyond the preview
Go deeper on 2005-003526-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003526-25.